Sutro Biopharma (STRO) Income from Continuing Operations (2017 - 2025)
Sutro Biopharma (STRO) reported Income from Continuing Operations of 46756000.0 for Q4 2025, up 35.46% on a YoY basis from 34516915.4 in Q4 2024, and up 17.77% sequentially from 56857000.0 in Q3 2025.
Sutro Biopharma (STRO) Income from Continuing Operations (2017 - 2025) Analysis & Trends
Sutro Biopharma (STRO) has 9 years of Income from Continuing Operations data on file, last reported at 46756000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 35.46% year-over-year to 46756000.0; the trailing twelve-month figure through Dec 2025 stood at 182737000.0 (up 19.66% YoY), and the FY2025 full-year result was 191080000.0, up 15.99% from the prior year.
- Income from Continuing Operations climbed to 46756000.0 in Q4 2025, from 56857000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 31057000.0 in Q4 2023 to a low of 72443000.0 in Q4 2024.
- A 5-year average of 36552600.0 and a median of 38817000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 189.78% in 2023 and sank 333.26% in 2024, its largest moves.
- Tracing STRO's Income from Continuing Operations over 5 years: stood at 38125000.0 in 2021, then rose by 9.26% to 34594000.0 in 2022, then surged by 189.78% to 31057000.0 in 2023, then sank by 333.26% to 72443000.0 in 2024, then surged by 35.46% to 46756000.0 in 2025.
- Business Quant data shows STRO's Income from Continuing Operations at 46756000.0 in Q4 2025, 56857000.0 in Q3 2025, and 11499000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Sutro Biopharma | 202.59 Mn | 61.16 Mn | - | -46.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -46.76 Mn |
| Sep 30, 2025 | -56.86 Mn |
| Jun 30, 2025 | -11.50 Mn |
| Mar 31, 2025 | -67.63 Mn |
| Dec 31, 2024 | -72.44 Mn |
| Sep 30, 2024 | -48.79 Mn |
| Jun 30, 2024 | -48.02 Mn |
| Mar 31, 2024 | -58.21 Mn |
| Dec 31, 2023 | 31.06 Mn |
| Sep 30, 2023 | -49.28 Mn |
| Jun 30, 2023 | -38.52 Mn |
| Mar 31, 2023 | -50.05 Mn |
| Dec 31, 2022 | -34.59 Mn |
| Sep 30, 2022 | -19.49 Mn |
| Jun 30, 2022 | -26.01 Mn |
| Mar 31, 2022 | -39.11 Mn |
| Dec 31, 2021 | -38.13 Mn |
| Sep 30, 2021 | -30.90 Mn |
| Jun 30, 2021 | -6.15 Mn |
| Mar 31, 2021 | -19.67 Mn |